Galantamine plasma concentration and cognitive response in Alzheimer’s disease

BACKGROUND: Galantamine has been approved for the treatment of Alzheimer’s disease (AD). However, there are few studies which have reported the association between cognitive responses and galantamine plasma concentration. The aim of this study was to determine the correlation between galantamine pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi-Ting, Chou, Mei-Chuan, Wu, Shyh-Jong, Yang, Yuan-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2019
Materias:
Cognitive Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500725/
https://www.ncbi.nlm.nih.gov/pubmed/31106076
http://dx.doi.org/10.7717/peerj.6887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500725/
https://www.ncbi.nlm.nih.gov/pubmed/31106076
http://dx.doi.org/10.7717/peerj.6887

Ejemplares similares